New Content Screening Platform Advances High-Conte?nt Analysis for Cancer Applicatio?ns
A new high-content screening software platform enables cancer researchers to uncover more about basic and advanced cellular function to accelerate cell-based research. The Thermo Scientific HCS Studio 2.0 is a high-content quantitative imaging and analysis software platform for a range of cancer research applications, including angiogenesis and migration/invasion, as well as the development of three-dimensional models of cancer stem cells and spheroid tumours.
The new Thermo Scientific HCS Studio 2.0, coupled with Thermo Scientific high content analysis platforms, are increasingly being used in cancer biology as they are well suited for large-scale, high-throughput biology, including complex morphological analyses of cells, cell structure, and aggregations of cells in colonies, yet simple enough to be applied to everyday assays such as viability and proliferation.
The Thermo Scientific HCS Studio 2.0 and the ArrayScan XTI High Content Analysis (HCA) platform will be demonstrated during the American Association for Cancer Research (AACR) 105th Annual Meeting (Booth #1107), 5–9 April 2014 at the San Diego Convention Center.
“The challenges posed by complex cancer applications and cell models demand new types of quantitative analysis techniques, and our new software continues to enable researchers with innovative assay techniques and functionality, allowing further discovery using complex cell models,” said Scott Keefer, manager of product marketing, cellular imaging and analysis, Thermo Fisher Scientific. “With our new HCS Studio 2.0 software, coupled with the Thermo Scientific ArrayScan XTI HCA Infinity Configuration enabled for 3D confocal imaging, our customers can address more assay and cell types than ever before while managing the complexities of high-content technology with user-guided, task-oriented software.”
Featuring a validated image processing tool and a powerful yet simple user interface, the HCS Studio 2.0 provides researchers with innovative assay techniques and functionality, allowing further discovery using complex cell models. Additional features include
• Directed Assay or Full Development Environment: Pick from validated assays or a customized design with a full suite of image processing tools
• Simple interactive tools for assay optimization: Best-in-class user tools to improve the performance and accuracy of image analysis on cells
• Seamless Integration: Works with software from Thermo Scientific High-Content Imaging platforms for a scalable quantitative cell analysis platform.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance